Hypothesis Comparison

⚛ Collide these ⚔ Judge as Duel

Comparing 2 hypotheses side-by-side

|

TREM2-ABI3 actin-phagocytosis coupling is a higher-yield AD target than either l

TREM2/ABI3 · Alzheimer's disease · combination_target
Composite
0.620
Price
$0.62
Evidence For
0
Evidence Against
0

TREM2 R47H and ABI3 rs616338 are both AD risk loci linked to microglial response, phagocytosis, and cytoskeletal remodeling. The notebook prioritizes them as a convergent module rather than isolated targets. Hypothesis: restoring TREM2-dependent lipid sensing together with ABI3-linked actin remodeling will rescue plaque engagement and debris clearance more robustly than modulating either locus alone in human iPSC-microglia.

Gut-derived butyrate reprograms microglia for amyloid clearance via HDAC2 inhibi

HDAC2 · Alzheimer's disease · mechanistic
Composite
0.000
Price
$0.50
Evidence For
0
Evidence Against
0

Specific butyrate-producing gut bacteria (e.g., Faecalibacterium, Roseburia) generate systemic butyrate that crosses the blood-brain barrier and inhibits hippocampal microglial HDAC2, leading to hyperacetylation of transcription factors that upregulate TREM2-independent phagocytic pathways. This enhances microglial amyloid-beta uptake and lysosomal degradation while suppressing NLRP3 inflammasome activation. Testable prediction: Germ-free AD mice colonized with butyrate-producing bacteria or tre

Convergent vs Divergent Predictions

This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.

Microglial PhagocytosisNeuroinflammationAlzheimer's disease
Convergent signals
  • No same-target convergence detected in this selection.
Divergent signals
  • No direct polarity conflicts detected among the selected hypotheses.

Verdict Summary

7/11
dimensions won
TREM2-ABI3 actin-phagocytosis coupling i
4/11
dimensions won
Gut-derived butyrate reprograms microgli

Radar Chart — 10 Dimensions

Score Comparison Bars

Mechanistic
0.68
0.00
Evidence
0.62
0.72
Novelty
0.61
0.68
Feasibility
0.57
0.78
Impact
0.70
0.00
Druggability
0.62
0.00
Safety
0.52
0.00
Competition
0.00
0.00
Data
0.75
0.00
Reproducible
0.60
0.00
KG Connect
0.50
0.50

Score Breakdown

DimensionTREM2-ABI3 actin-phagocytosis Gut-derived butyrate reprogram
Mechanistic0.6800.000
Evidence0.6200.720
Novelty0.6100.680
Feasibility0.5700.780
Impact0.7000.000
Druggability0.6200.000
Safety0.5200.000
Competition0.0000.000
Data0.7500.000
Reproducible0.6000.000
KG Connect0.5000.500

Evidence

TREM2-ABI3 actin-phagocytosis coupling is a higher-yield AD

No evidence citations yet

Gut-derived butyrate reprograms microglia for amyloid cleara

No evidence citations yet

Debate Excerpts

Gut-derived butyrate reprograms microglia for amyl

4 rounds · quality: 0.95

Theorist

Based on the literature provided, I'll generate novel therapeutic hypotheses targeting the gut-brain axis for Alzheimer's disease prevention and treatment: ## Hypothesis 1: Microglial Priming Reset v...

Skeptic

I'll provide a rigorous critique of each hypothesis based on the provided literature and scientific principles. ## Hypothesis 1: Microglial Priming Reset via SCFA Epigenetic Modulation **Critical We...

Domain Expert

I'll assess the practical feasibility of these gut-brain axis hypotheses for Alzheimer's disease, focusing on druggability, existing compounds, competitive landscape, and development timelines. ## OV...

Synthesizer

```json { "ranked_hypotheses": [ { "title": "Gut Barrier Reconstruction via Polysaccharide-Probiotic Synbiotics", "description": "Rosa roxburghii polysaccharides combined with specif...